ArticleMolecular biology reports2026
Impact of metformin-based chemo-radiotherapeutic strategies on breast cancer stemness and autophagy-associated gene expression: evidence from ALDH1A1 and LC3 expression analysis.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer remains a leading cause of cancer death worldwide, with treatment failure driven partly by cancer stem cells (CSCs) and dysregulated autophagy. Aldehyde dehydrogenase 1A1 (ALDH1A1) marks CSCs and indicates poor prognosis, whereas microtubule-associated protein 1 A/1B-light chain 3 (LC3) regulates autophagic flux. Metformin has anti-neoplastic activity, but its molecular effects during standard breast-cancer therapy remain incompletely defined. We evaluated the impact of metformin on ALDH1A1 and LC3 gene expression in patients receiving different chemo-radiotherapeutic regimens.
methodsIn this comparative, cross-sectional study, 86 early-stage breast cancer patients treated in the peri-operative (neoadjuvant or adjuvant) setting were grouped as chemotherapy only (n = 29), chemotherapy plus radiotherapy (n = 29), or chemotherapy plus radiotherapy plus metformin (n = 28); 30 healthy individuals served as controls. All major molecular subtypes (luminal A, luminal B, luminal B/HER2-positive, HER2-enriched and triple-negative) were represented across cohorts. ALDH1A1 and LC3 expression was quantified in peripheral blood mononuclear cells (PBMCs) by SYBR Green quantitative real-time PCR with GAPDH as the endogenous reference gene, using the 2 - ΔΔCt method. Non-parametric tests were applied.
resultsFold-change values were highly skewed and are reported as medians. ALDH1A1 expression decreased progressively across the chemotherapy (2.26), chemotherapy plus radiotherapy (0.75) and metformin (0.37) groups (H = 8.577, P = 0.014), being lowest in the metformin group (adjusted P = 0.039). LC3 expression rose progressively (4.18, 13.76 and 48.84; H = 24.177, P < 0.001), being highest with metformin (adjusted P < 0.001 versus chemotherapy alone; adjusted P = 0.021 versus chemotherapy plus radiotherapy). In receiver-operating-characteristic analysis, LC3 discriminated metformin-treated patients well (AUC = 0.80), and a combined ALDH1A1-LC3 model further improved discrimination (AUC = 0.91).
conclusionThe addition of metformin to chemo-radiotherapy was associated with lower ALDH1A1 and higher LC3 expression in peripheral blood mononuclear cells, consistent with engagement of cancer-stem-cell and autophagy-related pathways and supporting further evaluation of metformin as an adjuvant therapy. These associations do not by themselves establish a direct anti-tumour effect.
Indexed as
Identifiers
42377636What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.